Allogeneic hematopoietic stem cell transplantation mortality has declined over the years, though prevention and management of treatment-related toxicities and post-transplant complications remains challenging. Applications of pharmacogenomic testing can potentially mitigate adverse drug outcomes due to interindividual variability in drug metabolism and response. This review summarizes clinical pharmacogenomic applications relevant to hematopoietic stem cell transplantation, including antifungals, immunosuppressants, and supportive care management, as well as emerging pharmacogenomic evidence with conditioning regimens.
Keywords: Allogeneic transplantation; Bone marrow transplant; Hematopoietic stem cell transplantation; Pharmacogenetics; Pharmacogenomics; Supportive care.
Copyright © 2023 Elsevier Ltd. All rights reserved.